Guidance document from Health Canada on biosimilar submission requirements

December 26, 2016 7:50 AM

canada-flag

Last month, Health Canada revised the guidance on Information and Submission Requirements for Biosimilar Biologic Drugs.

Health Canada, the federal regulatory authority that evaluates the safety, efficacy, and quality of drugs available in Canada, recognises that with the expiration of patents for biologic drugs, manufacturers may be interested in pursuing subsequent entry versions of these biologic drugs. The term biosimilar biologic drug, referred to as biosimilar, is used by Health Canada to describe subsequent entry versions of a Canadian approved innovator biologic with demonstrated similarity to a reference biologic drug.

Biosimilars were previously referred to as Subsequent Entry Biologics (SEBs) in Canada. With this new guidance, Health Canada, accepts to use the term “biosimilar” like FDA and other major agencies.

The English version of the updated guidance document can be found here.

 

 

 

 

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!